Bulletin
Investor Alert

NeuBase Therapeutics Inc.

NAS: NBSE

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 22, 2021, 6:40 p.m.

/zigman2/quotes/206101919/composite

$

4.48

Change

+0.44 +10.89%

Volume

Volume 1

Quotes are delayed by 20 min

/zigman2/quotes/206101919/composite

Previous close

$ 4.18

$ 4.04

Change

-0.14 -3.35%

Day low

Day high

$3.98

$4.22

Open

52 week low

52 week high

$3.26

$12.89

Open

Annual Financials for NeuBase Therapeutics Inc.

Fiscal year is October-September. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue -----
Cost of Goods Sold (COGS) incl. D&A 1.19M1.17M-128,372280,463
COGS excluding D&A -----
Depreciation & Amortization Expense 1.19M1.17M-128,372280,463
Depreciation 64,63245,072-28,372100,000
Amortization of Intangibles 1.12M1.12M-100,000180,463
Gross Income (1.19M)(1.17M)-(128,372)(280,463)
20162017201820192020 5-year trend
SG&A Expense 24.12M22.69M41,21225.38M16.79M
Research & Development 16.46M17.41M12,81916.39M6.85M
Other SG&A 7.66M5.28M28,3939M9.94M
Other Operating Expense -(70,760)---
Unusual Expense 475,403--492,889453,808
EBIT after Unusual Expense (25.78M)--(492,889)(17.52M)
Non Operating Income/Expense 3,420(1,350)--409,140
Non-Operating Interest Income 12,103----
Equity in Affiliates (Pretax) ----(262,861)
Interest Expense -29,574740128,9517,686
Gross Interest Expense -29,574740128,9517,686
Interest Capitalized -----
Pretax Income (25.77M)(23.81M)(41,952)(26.13M)(17.38M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (25.77M)(23.81M)(41,952)(26.13M)(17.38M)
Minority Interest Expense -----
Net Income (25.77M)(23.81M)(41,952)(26.13M)(17.38M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (25.77M)(23.81M)(41,952)(26.13M)(17.38M)
Preferred Dividends -----
Net Income Available to Common (25.77M)(23.81M)(41,952)(26.13M)(17.38M)
EPS (Basic) (16.40)(10.60)(0.15)(3.16)(0.89)
Basic Shares Outstanding 1.57M2.24M286,3558.27M19.62M
EPS (Diluted) (16.40)(10.60)(0.15)(3.16)(0.89)
Diluted Shares Outstanding 1.57M2.24M286,3558.27M19.62M
EBITDA (24.12M)(22.61M)(41,210)(25.38M)(16.79M)
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.